PsyAccess
PATPending re-verificationPrivate-market model

OVID Clinic Berlin (Compassionate Use)

Berlin, Germany

Treatment & access

  • Treatments offeredpsilocybin
  • Access routecompassionate_use
  • Price informationNo price published; psilocybin (PEX010) administered within authorised Expanded Access Programme; treatment embedded in multi-week day-clinic programme (day clinic ca. EUR 15,000 / 6 weeks, PKV usually covers)
  • Phone+49 30 257 699 69 (Tagesklinik)
  • Websitehttps://ovid-clinics.de

About this provider

Compassionate-use arm of OVID Clinics Berlin: under the direction of Prof. Dr. Gerhard Gruender, individual adult patients with treatment-resistant depression can receive psilocybin (PEX010, Filament Health) at the OVID day clinic in Berlin within Germany's first authorised Expanded Access (Compassionate Use) Programme, run jointly with the Central Institute of Mental Health (ZI) Mannheim since July 2025. It is not a regular therapy offer: eligibility requires a serious illness, no satisfactory approved treatment and no possibility of trial participation, with case-by-case benefit-risk review.

Services & programs

  • Psilocybin single-dose treatment with accompanying psychotherapy (preparation and follow-up), within multi-week day-clinic setting

Programs & studies

ProgramKindStatus
Psilocybin Expanded Access Programme for treatment-resistant depression (with ZI Mannheim; PEX010 / Filament Health)active since 11 July 2025; exceptional cases only

Facilities & languages

  • Facilities
    • OVID Tagesklinik, Boxhagener Str. 82, Berlin
  • LanguagesGerman, English, Spanish, Turkish (clinic-wide)
  • TeamProf. Dr. med. Gerhard Gruender (programme director, licence holder); Dr. med. Andrea Jungaberle (holds OVID's psilocybin treatment licence)

Common questions

Can I apply for psilocybin treatment?

Only in justified exceptional cases: adults with treatment-resistant depression, no satisfactory approved treatment available, and participation in a clinical trial not possible; each case undergoes benefit-risk review.

Is the programme a route to regular psilocybin therapy?

No. ZI/OVID state the Compassionate Use Programme cannot replace regulatory approval and that demand will significantly exceed capacity.

Verification

This record was verified previously and is awaiting its scheduled re-check against the registry.

  • License / registryPublic trial registry (ClinicalTrials.gov / EU CTIS)
  • Sourcehttps://ovid-clinics.de
  • Last verified

Spotted an error? See our methodology for how records are checked and how to report a correction.